Bio-IT World March 9, 2020
Contributed Commentary by Ferdi Steinmann

Achieving a single view of the patient has been a key challenge for the life sciences industry, given the inherently siloed nature of organizations in the sector. However, as patient centricity increasingly becomes the crux of all life science organizations, the pace of digitization within the industry has picked up significantly.

Organizations have been quick to understand the need to implement transformative technologies such as AI, analytics, IoT, blockchain and cloud platforms, to create a world of patient centricity and personalized, value- based medicines. Here are eight ways digital technologies will shape each stage of the drug lifecycle.

Research and development

Like many other areas of life sciences, research and development (R&D) organizations have lagged behind their stakeholders—especially patients—in their...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Digital Health, Health IT, Provider, Technology
BMS plans $1.5B in cuts through '25, with 2000-plus layoffs
Big Pharma's ROI for drug R&D saw 'welcome' rebound in 2023: report
STAT+: Why a British hospital, and not a drugmaker, is trying to get a rare disease therapy approved
STAT+: Profiting from ‘legal’ insider trading isn’t always easy
Regeneron expands in gene editing with Mammoth deal

Share This Article